Media
Bod Science raises £1.9m to ease pressure on R&D costs
03 Aug 2023
Published by: Cannabiz
Study delivers ‘new chapter’ for Bod as Aqua Phase tech shows its worth
26 Jul 2023
Published by: Cannabiz
BOD’s CBD product improves bioavailability by 311%
25 Jul 2023
Published by: Next Investors
ASX Health Stocks: BOD to acquire Aqua Phase on positive data; Bionomics set to delist
25 Jul 2023
Published by: Stockhead
Bod plotting ‘immediate’ overseas move if CBD sleep trial succeeds
19 Jul 2023
Published by: Cannabiz
Bod Completes Trial Of Schedule 3 Cannabidiol Contender
13 Jul 2023
Published by: Hemp Gazette
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
13 Jul 2023
Published by: Stockhead
Bod Science Limited (ASX:BOD) Investor Presentation | July 2023
13 Jul 2023
Published by: Bod Science
Bod Science faces nervy wait as final patient completes S3 clinical trial
10 Jul 2023
Published by: Cannabiz
